LÖLevent Özsarı

Levent Özsarı

*This is an algorithmically generated author record based on publicly available information.

Levent Özsarı has a total of 64 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Genetic spectrum and genotype–phenotype associations in Paget's disease of bone: A nationwide multicenter study from Türkiye

    by Dilek Gogas Yavuz, Hazal Şalva, Pınar Ata, Ebru Arslan, Onur Hanoğlu, Mahsan Azimi, Zeliha Hekimsoy, Hakan Doğruel, Ramazan Sarı, Feyza Yener Öztürk, et al.

  • Open Access

    Can Hemoglobin, Albumin, Lymphocyte, and Platelet (HALP) Score Predict Adrenal Incidentaloma Growth?

    by Levent Ozsari, Cem Dogan, Akin Dayan

    Objective: The optimal management and follow-up strategies for adrenal incidentalomas (AIs) remain controversial, with conflicting guidelines on routine imaging versus surveillance. This study investigates the prognostic utility of the Hemoglobin, Albumin, Lymphocyte, and Platelet (HALP) score, previously validated in malignancies, as a potential predictor of AI growth over a one-year period. Methods: This retrospective study included 66 female patients (aged 18–80 years) with incidentally detected adrenal masses, who underwent at least two imaging scans within a one-year period. The HALP score at diagnosis and the change in adrenal mass diameter between baseline and follow-up imaging were assessed. Growth of adrenal mass was defined as an increase in diameter ≥3 mm. Results: Patients with growing AIs exhibited lower baseline HALP scores compared to those with stable lesions (p = 0.093). A significant negative correlation was observed between HALP score and diameter change in a subgroup of patients with growth ≥3 mm (Spearman’s rho = -0.766, p = 0.010). However, HALP score was not a significant predictor of AI growth according to logistic regression analysis (p > 0.05). Conclusion: Although an inverse association exists between the HALP score and AI growth, it lacks sufficient predictive accuracy to serve as a standalone marker for short-term prognosis. Larger-scale, long-term studies are needed to explore its potential role in AI management.

  • Open Access

    The Effects of Gluten on Weight Gain, Hematological, Biochemical, and Various Endocrinological Parameters

    by Atilla Bektaş, Meltem Ulusoy, Levent Özsarı, Ahmet Melih Özel

    Background/Aims: This study is aimed to compare the effects of nutrition which has been enriched with different amounts of gluten to gluten-free diets on weight gain, diabetogenic state, hematological, and biochemical parameters. Materials and Methods: A total of 40 newly weaned male Wistar albino rats used in the study were randomized into 4 different groups based on the gluten rations they were given. Following 12 weeks of diet they were killed and intracardiac blood samples were collected. Groups were identified as group 1 (n = 10): control group; normal rat ration containing wheat, group 2 (n = 10): gluten-free diet, group 3 (n = 10): ration containing medium level of gluten (normal rat diet+6% vital gluten) and group 4 (n = 10): ration containing high level of gluten (normal rat diet+12% vital gluten). Results: In groups 3 and 4, high-density lipoprotein was found to be higher than the other 2groups. However, when group 2 results were compared to the other groups; the highest T3, T4, creatinine and B12 levels and the lowest gluten-specific IgE level were observed. alanine aminotransferase and aspartate aminotransferase levels were found to be higher in group 1 compared to the other 3 groups. No statistically significant difference was detected between the groups in terms of other parameters. Conclusion: This study provides evidence that a gluten-containing diet does not cause weight gain, has no diabetogenic effect, and also does not adversely affect general health in relation to hematological, biochemical, and various endocrinological parameters. Cite this article as: Bektaş A, Ulusoy M, özsarı L, özel AM. The effects of gluten on weight gain, hematological, biochemical, and various endocrinological parameters. Turk J Gastroenterol. 2024;35(3):178-185.


  • Assesment of attainment of recommended TSH levels and levothyroxine compliance in differentiated thyroid cancer patients

    by Dilek Gogas Yavuz, Ceyda D. Yazan, Zeliha Hekimsoy, Kadriye Aydin, Naile Gokkaya, Canan Ersoy, Aysen Akalın, Omercan Topaloglu, Berna I. Aydogan, Esra N. A. Dilekci, et al.

    Objective: Thyroid‐stimulating hormone (TSH) suppression treatment can induce signs and symptoms of hyperthyroidism and hypothyroidism due to inappropriate treatment or poor compliance to the treatment. The current study aimed to investigate TSH levels, frequency of being on target TSH, adherence to levothyroxine (LT4) suppression treatment in differentiated thyroid cancer (DTC) patients after surgery in a multicentric setting.Design and Patients: This multicentric cross‐sectional study was conducted at 21 medical centres from 12 cities in Turkey. DTC patients followed at least one year in the same center included in the study. Clinical data, serum TSH, free thyroxine (FT4), thyroglobulin (Tg) and anti‐Tg levels were recorded during the most recent visit. Body mass index, systolic and diastolic blood pressures, pulse rate were measured. LT4 doses were recorded and doses per kilogram of bodyweight were calculated. Pill ingestion habits recorded and adherence to the therapy were evaluated using the Morisky Medication Adherence Scale and categorized as good, moderate or poor compliant based on their scores. Risk stratification forpredicting the disease persistance and/or reccurence was assessed using the American Joint Committee on Cancer‐7th edition thyroid cancer staging calculator. TSH serum concentrations were classified as severe suppression (TSH < 0.01 mU/L), moderate suppression (TSH: 0.01–0.1 mU/L), mild suppression (TSHL 0.1–0.5 mU/L), euthyroid (TSH: 0.5–4 mU/L) and hypothyroid (TSH > 4 mU/L). TSH levels can also be classified as on being on target, under the target, or beyond over the target, according to the American Thyroid Association recommendations.Results: A group of 1125 patients (F/M: 941/184, 50.7 ± 11.7 years) were included in the study. The mean LT4 daily dosage was 132.4 ± 39.6 mcg/day. TSH levels showed severe suppression in 99 (%8.8) patients, moderate suppression in 277 (%24.6) patients and mild suppression in 315 (%28) patients and euthyroid range in 332 (%29.5) patients and hypothyroid range in 97 (8.6%). TSH levels were in target in 29.2% of the patients 20.4% of the patients were undertreated, 50.4% overtreated. The daily LT4 dose and LT4 dose/kg were significantly higher in the severe suppression group (p < .001, p < .001). According to the Morisky scale, 564 patients (50.1%) were good compliant, 368 patients (32.7%) were moderate compliant, and 193 patients (17.1%) were noncompliant. Patients with poor compliance need a higher dose of LT4 compared to the good compliance group (p < .001). TSH levels of patients with good compliance were 0.67 ± 1.96 mU/L and TSH with poor compliance was 2.74 ± 7.47 mU/L (p < .001). TSH levels were similar in patients on fixed and alternating dosages.Conclusion: In 29.2% of the DTC patients, serum TSH levels were at target levels. Remaining of the study group have TSH levels under or over treatment range, exposing the patient to medication side effects. Majorty of the study group 82.8% have good or moderate adherence to LT4 therapy. Reaching TSH targets requires simplified and applicable guidelines and following the guideline recommendations.